Tysabri Clears FDA For Moderate To Severe Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.
You may also be interested in...
Tysabri Continues Comeback; On Pace To Reach 100,000 Patients In 2010
The once-withdrawn MS drug continues to gain patients in the U.S. and EU, with an improving safety profile, Biogen says.
Tysabri Continues Comeback; On Pace To Reach 100,000 Patients In 2010
The once-withdrawn MS drug continues to gain patients in the U.S. and EU, with an improving safety profile, Biogen says.
Biogen Idec Clears The Air: No Large Companies Meet Dual Test For Acquisition
Putting a “permanent for sale sign out on the front lawn” is not the appropriate way to run the biotech either, CEO Mullen maintains.